Literature DB >> 10225571

Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose.

M C Birmingham1, R Guarino, A Heller, J H Wilton, A Shah, L Hejmanowski, D E Nix, J J Schentag.   

Abstract

Intravenous ciprofloxacin is frequently prescribed for the treatment of infections due to nosocomially acquired gram-negative organisms, including those originating in the respiratory tract. In this study, the concentrations of ciprofloxacin in serum and lung tissue were determined by HPLC in patients undergoing lung surgery. A total of 22 patients scheduled for lung surgery received a single 400 mg i.v. dose of ciprofloxacin administered as a 1 h infusion. A specimen of healthy lung tissue was obtained from resected lung from 18 of the patients for analysis of ciprofloxacin concentration during the following time intervals after infusion (one sample/patient): 0-2, 2-4, 4-8 and 8-12 h. Corresponding mean serum and tissue concentrations were 2.37 mg/L and 3.84 mg/kg (0-2 h), 1.18 mg/L and 1.92 mg/kg (2-4 h), 0.69 mg/L and 1.77 mg/kg (4-8 h), and 0.13 mg/L and 0.67 mg/kg (8-12 h). Ciprofloxacin distributed rapidly to lung tissue, as seen by the high concentrations in the lung tissue as early as 2 h after infusion. Concentrations in lung tissue were generally higher than those in serum (tissue:serum ratios ranged from 1.7 to 7.1). The mean tissue concentrations found in this study remained above the MIC for most susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225571     DOI: 10.1093/jac/43.suppl_1.43

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose.

Authors:  Florian Islinger; Rene Bouw; Mathias Stahl; Edith Lackner; Petra Zeleny; Martin Brunner; Markus Müller; Hans Georg Eichler; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells.

Authors:  Raquel Garcia-Medina; W Michael Dunne; Pradeep K Singh; Steven L Brody
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Tissue pharmacokinetics of levofloxacin in human soft tissue infections.

Authors:  Romuald Bellmann; Gerald Kuchling; Pejman Dehghanyar; Markus Zeitlinger; Erich Minar; Bernhard X Mayer; Markus Müller; Christian Joukhadar
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

5.  [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans.

Authors:  Martin Brunner; Oliver Langer; Georg Dobrozemsky; Ulrich Müller; Markus Zeitlinger; Markus Mitterhauser; Wolfgang Wadsak; Robert Dudczak; Kurt Kletter; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study.

Authors:  Koen P van Rhee; Cornelis Smit; Roeland E Wasmann; Paul D van der Linden; Rene Wiezer; Eric P A Van Dongen; Elke H J Krekels; Roger J M Brüggemann; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2022-06-01       Impact factor: 5.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.